Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20617537 | 0.82 | L3MBTL1 (0.53) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL8603867 | 0.82 | — | — | |
| SCHEMBL5543470 | 0.82 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL6043729 | 0.82 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL13472660 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL771532 | 0.79 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL13672766 | 0.79 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL772776 | 0.79 | CYP2D6 (0.45) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL8488026 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL8488022 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2POLBHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-6844366-B2 | Sulfonamide hydroxamates | SYNTEX (U.S.A.) LLC (US) | 2005-01-18 | — | — | US | disclosed |
| US-6787559-B2 | HYDROXYCARBONYL OR ALKYLOXYCARBONYL OR AMINOHYDROXYCARBONYL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PROCOLLAGEN C-PROTENASE INHIBITOR | SYNTEX (U.S.A.) LLC. | 2004-09-07 | — | — | US | disclosed |
| EP-1149072-B1 | SULFONAMIDE HYDROXAMATES | HOFFMANN LA ROCHE (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | BILLLEDEAU ROLAND JOSEPH (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030199520-A1 | Sulfonamide hydroxamates | BILLLEDEAU ROLAND JOSEPH (US) | 2003-10-23 | — | — | US | disclosed |
| US-6492394-B1 | PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES | SYNTEX (U.S.A.) LLC | 2002-12-10 | — | — | US | disclosed |
| EP-1149072-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000037436-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| CN-1136556-A | Aromatic group substituted W-amino alkyl amide and alkyl amide | CIBA GEIGY CO LTD (CH) | 1996-11-27 | — | — | CN | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | CTSE, PREP, HPN | ALDH1A1 3050/4885SMN1; SMN2 2079/4885POLB 815/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885SMN1; SMN2 4306/4885POLB 77/4885 |
| US-20030199520-A1 | Sulfonamide hydroxamates | MMP3, TIMP3, MMP13 | ALDH1A1 2158/4885SMN1; SMN2 2128/4885POLB 2518/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | ALDH1A1 351/4885SMN1; SMN2 4399/4885POLB 308/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885SMN1; SMN2 4306/4885POLB 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.